Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
Por um escritor misterioso
Descrição
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.
FDA Approves New Schizophrenia, Depression Drug Brexpiprazole - Psychiatry Advisor
REXULTI® (brexpiprazole), MDD
ex9901_img001.jpg
Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human
Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC
Brexpiprazole Updated - Gateway Psychiatric
Brexpiprazole - NeuRA Library
Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® ( brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease
1mg REXULTI TABLET, Schizophrenia, Intas Pharmaceuticals
For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)
de
por adulto (o preço varia de acordo com o tamanho do grupo)
